ClinicalTrials.gg
CompletedNCT00387881Updated Dec 16, 2016Results posted

TREXIMET (Formerly Known as TREXIMA) for the Acute Treatment of Probable Migraine (ICHD-II 1.6.1)

A Phase 3 interventional study of sumatriptan succinate / naproxen sodium and Placebo in Migraine, Without Aura, sponsored by GlaxoSmithKline. Completed at 70 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-12-16.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
679
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 31 studies in Migraine without Aura with a site in United States — 5 open to participants now, 6 under way, none of them phase 3. Migraine without Aura · United States.

Enrollment
3rd of 30
679 · median 96
Started
2006
the only one that year
Phase 3
5 of 31
none open now
Registered
2nd of 31
by date

Among the 31 studies in Migraine without Aura with a site in United States, this one is the 3rd largest by enrollment of the 30 interventional ones that give a count, is the only one that started in 2006, is one of 5 in phase 3, and was the 2nd registered.

Migraine without Aura

109 studies on the registry are indexed under Migraine without Aura; 17 are open to participants now.

Browse Migraine without Aura studies →

Open to participants now

5 of the 31 studies in Migraine without Aura with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Migraine without Aura studies recruiting now, 5 (42%) set no upper age limit and 7 (58%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Migraine without Aura with a site in United States, or all of them as a file.
02

Study summary

This study was designed to determine the efficacy and tolerability of TREXIMET (formerly known as TREXIMA) compared to placebo for the acute treatment of probable migraine, a sub-type of migraine.

03

Conditions studied

  • Migraine, Without Aura

Keywords

  • sumatriptan succinate,
  • naproxen sodium,
  • parallel group,
  • double-blind,
  • placebo-controlled,
  • Combination product,
  • migrainous headache
  • Probable migraine, a sub-type of Migraine
  • probable migraine,
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least a 6 month history of probably migraine (6 migraine attacks per month)
  • Males and women of on a adequate .

Exclusion criteria

Exclusion Criteria:

  • Physician diagnosis of migraine; history of triptan or ergot use; history of headache prophylaxis use
  • Pregnant and/or nursing mother
  • History of cardiovascular disease.
  • Uncontrolled hypertension.
  • Basilar or Hemiplegic migraine
  • History of stroke or (TIA).
  • History of epilepsy or treated with anti-epileptics within the past 5 years.
  • Impaired hepatic or renal function.
  • History of gastrointestinal bleeding or ulceration.
  • Allergy or to Aspirin or any other NSAID.
  • Allergy or hypersensitivity to triptans.
  • Participated in an drug trial in the previous 4 weeks.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
679 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Experimental
    Treximet

    Drug: sumatriptan succinate / naproxen sodium

Interventions

06

What researchers measure

Primary outcomes

  1. Pain-Free at 2 Hours Post-dose and Sustained Pain-Free From 2-24 Hours Post-dose.

    Pain-free was defined as a headache severity of no pain (grade 0) at 2 hours post-treatment in subjects who have not used rescue medication prior to or at the time of the assessment. Sustained pain-free response was defined as pain-free at 2 hours post-treatment through 24 hours post-treatment without rescue medicine.

    Time frame: 2 hours through 24 hours after Treatment

Secondary outcomes

  1. Freedom From Headache Pain at 0.5, 1, and 4 Hours After Treatment

    Pain-Free is defined as post-treatment headache pain severity of none in subjects who have not used rescue medication prior to or at the time of the assessment.

    Time frame: 0.5, 1, and 4 hours after Treatment

  2. Sustained Headache Relief 2-24 Hours After Treatment

    Sustained pain relief was defined as having pain relief (mild or no pain) at 2 hours w/o any moderate or severe pain during 2-24 hour period post-treatment, without rescue medication.

    Time frame: 2-24 hours after treatment

  3. Headache Relief at 4, 2, 1 and 0.5 Hours After Treatment

    Pain relief was defined as reduction of headache pain from a baseline severity of moderate or severe to none or mild at the given time.

    Time frame: 0.5, 1, 2, and 4 hours after treatment

  4. Subjects Who Used Rescue Medication From 0 - 24 Hours After Treatment

    Rescue medication defined as additional medication (i.e. sumatriptan/naproxen sodium as open-label rescue or other medication as permitted per protocol), taken by subject for the treatment of headache pain or other symptoms associated with the headache attack.

    Time frame: 0 - 24 hours after treatment

  5. Intermediate Sustained Pain Relief: Post-dose at Intervals of 2-4 Hours and 1-2 Hours After Treatment

    Intermediate sustained pain relief was defined as achieving headache pain relief (from moderate or severe pain at baseline to mild or no pain) prior to the specified timepoint (1 or 2 hours) and maintaining it to the specified timepoint (2-4 hours). (Intermediate=Intermed.)

    Time frame: 1-2, and 2- 4 hours after treatment

  6. Intermediate Sustained Pain-Free: Post-dose at Intervals of 2-4 Hours and 1-2 Hours

    Intermediate sustained pain free was defined as achieving headache pain-free (moderate or severe pain to no pain) prior to the specified timepoint (1 or 2 hours) and maintaining it to the specified timepoint (2-4 hours).(Intermediate=Intermed.)

    Time frame: 1-2 and 2-4 hours after treatment

  7. Incidence of Headache Associated: Neck Pain, Sinus Pain, Photophobia, Phonophobia, Nausea at Time Intervals of 4 and 2 Hours After Treatment

    Neck pain, sinus pain, photophobia, phonophobia and nausea are considered headache-associated symptoms.(Headache-associated=Headache-Assoc.)

    Time frame: 2 and 4 hours after treatment

  8. Medication Satisfaction: Mean Patient Perception of Migraine (PPMQ-R) Subscale Score

    Patient Perception of Migraine Questionnaire-Revised(PPMQ-R) evaluates subject satisfaction with treatment 24 hours post-dose using validated questions. Questions are analyzed on 4 subscale scores (efficacy, functionality, ease-of-use, and tolerability) and total score. Scores range from 0-100, with the higher scores indicating better satisfaction.

    Time frame: 0 - 24 hours after treatment

07

Results

Posted Jul 10, 2009

Participant flow

Participant flow — Overall Study
MilestonePlaceboSumatriptan/Naproxen
Started334345
Completed245243
Not completed89102
Withdrew: Lost to follow-up2323
Withdrew: Protocol violation212
Withdrew: Withdrawal by subject1518
Withdrew: Sponsor terminated study01
Withdrew: Not eligible67
Withdrew: No opportunity to treat headache3234
Withdrew: Not otherwise specified117

Outcome measures

PrimaryPain-Free at 2 Hours Post-dose and Sustained Pain-Free From 2-24 Hours Post-dose.

Pain-free was defined as a headache severity of no pain (grade 0) at 2 hours post-treatment in subjects who have not used rescue medication prior to or at the time of the assessment. Sustained pain-free response was defined as pain-free at 2 hours post-treatment through 24 hours post-treatment without rescue medicine.

Time frame:
2 hours through 24 hours after Treatment
Reported as:
Number · Participants
Pain-Free at 2 Hours Post-dose and Sustained Pain-Free From 2-24 Hours Post-dose.
ParticipantsPlaceboSumatriptan/Naproxen
Pain-Free (2 hours)2564
Sustained Pain-Free (2-24 hours)2054
Statistical analysis
  • Placebo vs Sumatriptan/Naproxen · Cochran-Mantel-Haenszel · p = <0.001 (Endpoints were co-primary and both needed to have p-value of \<0.05 to be considered indicative of efficacy.) · Percent difference: 18 · 95% CI 10 to 25Analysis for Migraine Pain-Free at 2 hours Post-Dose
  • Placebo vs Sumatriptan/Naproxen · Cochran-Mantel-Haenszel · p = <0.001 · Percent difference: 15 · 95% CI 8 to 22Analysis for Sustained Pain Free from 2-24 hours Post-dose
SecondaryFreedom From Headache Pain at 0.5, 1, and 4 Hours After Treatment

Pain-Free is defined as post-treatment headache pain severity of none in subjects who have not used rescue medication prior to or at the time of the assessment.

Time frame:
0.5, 1, and 4 hours after Treatment
Reported as:
Number · Participants
Freedom From Headache Pain at 0.5, 1, and 4 Hours After Treatment
ParticipantsPlaceboSumatriptan/Naproxen
Pain-free at 4 hours60105
Pain-free at 1 hour1623
Pain-free at 0.5 hour65
SecondarySustained Headache Relief 2-24 Hours After Treatment

Sustained pain relief was defined as having pain relief (mild or no pain) at 2 hours w/o any moderate or severe pain during 2-24 hour period post-treatment, without rescue medication.

Time frame:
2-24 hours after treatment
Reported as:
Number · Participants
Sustained Headache Relief 2-24 Hours After Treatment
ParticipantsPlaceboSumatriptan/Naproxen
Sustained Headache Relief 2-24 Hours After Treatment77110
SecondaryHeadache Relief at 4, 2, 1 and 0.5 Hours After Treatment

Pain relief was defined as reduction of headache pain from a baseline severity of moderate or severe to none or mild at the given time.

Time frame:
0.5, 1, 2, and 4 hours after treatment
Reported as:
Number · Participants
Headache Relief at 4, 2, 1 and 0.5 Hours After Treatment
ParticipantsPlaceboSumatriptan/Naproxen
Headache relief at 4 hours108153
Headache relief at 2 hours113124
Headache relief at 1 hour7385
Headache relief at 0.5 hour3941
SecondarySubjects Who Used Rescue Medication From 0 - 24 Hours After Treatment

Rescue medication defined as additional medication (i.e. sumatriptan/naproxen sodium as open-label rescue or other medication as permitted per protocol), taken by subject for the treatment of headache pain or other symptoms associated with the headache attack.

Time frame:
0 - 24 hours after treatment
Reported as:
Number · Participants
Subjects Who Used Rescue Medication From 0 - 24 Hours After Treatment
ParticipantsPlaceboSumatriptan/Naproxen
Subjects Who Used Rescue Medication From 0 - 24 Hours After Treatment10161
SecondaryIntermediate Sustained Pain Relief: Post-dose at Intervals of 2-4 Hours and 1-2 Hours After Treatment

Intermediate sustained pain relief was defined as achieving headache pain relief (from moderate or severe pain at baseline to mild or no pain) prior to the specified timepoint (1 or 2 hours) and maintaining it to the specified timepoint (2-4 hours). (Intermediate=Intermed.)

Time frame:
1-2, and 2- 4 hours after treatment
Reported as:
Number · Participants
Intermediate Sustained Pain Relief: Post-dose at Intervals of 2-4 Hours and 1-2 Hours After Treatment
ParticipantsPlaceboSumatriptan/Naproxen
Intermed. Sustained Pain Relief, 2-4 hrs post-dose92118
Intermed. Sustained Pain Relief, 1-2 hrs post-dose6784
SecondaryIntermediate Sustained Pain-Free: Post-dose at Intervals of 2-4 Hours and 1-2 Hours

Intermediate sustained pain free was defined as achieving headache pain-free (moderate or severe pain to no pain) prior to the specified timepoint (1 or 2 hours) and maintaining it to the specified timepoint (2-4 hours).(Intermediate=Intermed.)

Time frame:
1-2 and 2-4 hours after treatment
Reported as:
Number · Participants
Intermediate Sustained Pain-Free: Post-dose at Intervals of 2-4 Hours and 1-2 Hours
ParticipantsPlaceboSumatriptan/Naproxen
Intermed. Sustained Pain-free, 2-4 hrs post-dose2261
Intermed. Sustained Pain-free, 1-2 hrs post-dose1123
SecondaryIncidence of Headache Associated: Neck Pain, Sinus Pain, Photophobia, Phonophobia, Nausea at Time Intervals of 4 and 2 Hours After Treatment

Neck pain, sinus pain, photophobia, phonophobia and nausea are considered headache-associated symptoms.(Headache-associated=Headache-Assoc.)

Time frame:
2 and 4 hours after treatment
Reported as:
Number · Participants
Incidence of Headache Associated: Neck Pain, Sinus Pain, Photophobia, Phonophobia, Nausea at Time Intervals of 4 and 2 Hours After Treatment
ParticipantsPlaceboSumatriptan/Naproxen
Headache-Assoc. Neck Pain at 4 hours9363
Headache-Assoc. Neck Pain at 2 hours6859
Headache-Assoc. Sinus Pain at 4 hours8849
Headache-Assoc. Sinus Pain at 2 hours4936
Headache-Assoc. Photophobia at 4 hours8760
Headache-Assoc. Photophobia at 2 hours6046
Headache-Assoc. Phonophobia at 4 hours8359
Headache-Assoc. Phonophobia at 2 hours5354
Headache-Assoc. Nausea at 4 hours8251
Headache-Assoc. Nausea at 2 hours3736
SecondaryMedication Satisfaction: Mean Patient Perception of Migraine (PPMQ-R) Subscale Score

Patient Perception of Migraine Questionnaire-Revised(PPMQ-R) evaluates subject satisfaction with treatment 24 hours post-dose using validated questions. Questions are analyzed on 4 subscale scores (efficacy, functionality, ease-of-use, and tolerability) and total score. Scores range from 0-100, with the higher scores indicating better satisfaction.

Time frame:
0 - 24 hours after treatment
Reported as:
Mean · Score in scale
Medication Satisfaction: Mean Patient Perception of Migraine (PPMQ-R) Subscale Score
Score in scalePlaceboSumatriptan/Naproxen
Efficacy Adjusted Mean53 ± 2.067 ± 2.0
Functionality Adjusted Mean56 ± 2.170 ± 2.1
Ease-of-Use Adjusted Mean84 ± 1.388 ± 1.3
Bothersome-of-Side Effects Adjusted Mean94 ± 0.891 ± 0.8
Total Score adjusted Mean64 ± 1.575 ± 1.6

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/246 (0%)0/246 (0%)
Sumatriptan/Naproxen—0/254 (0%)0/254 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboSumatriptan/NaproxenTotal
Mean36.6 ± 11.2335.8 ± 11.4736.2 ± 11.35
Gender
Gender(Participants)PlaceboSumatriptan/NaproxenTotal
Female176195371
Male7059129
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboSumatriptan/NaproxenTotal
African American/African Heritage283058
American Indian or Alaskan Native101
Asian - East Asian Heritage6814
Asian - Japanese Heritage213
Asian - South East Asian Heritage8513
Native Hawaiian or other Pacific Islander101
White - Arabic/North African Heritage123
White - White/Caucasian/European Heritage199206405
Mixed race011
Missing011
08

Study locations

70 sites
  • GSK Investigational Site
    Phoenix, Arizona 85014, United States
  • GSK Investigational Site
    Phoenix, Arizona 85050, United States
  • GSK Investigational Site
    Little Rock, Arkansas 72205, United States
  • GSK Investigational Site
    Anaheim, California 92801, United States
  • GSK Investigational Site
    Anaheim, California 92805, United States
  • GSK Investigational Site
    Buena Park, California 90620, United States
  • GSK Investigational Site
    Diamond Bar, California 91765, United States
  • GSK Investigational Site
    Newport Beach, California 92660, United States
  • GSK Investigational Site
    San Diego, California 92128, United States
  • GSK Investigational Site
    San Francisco, California 94109, United States
  • GSK Investigational Site
    Santa Monica, California 90404, United States
  • GSK Investigational Site
    Walnut Creek, California 94596, United States
  • GSK Investigational Site
    Westlake Village, California 91361, United States
  • GSK Investigational Site
    Colorado Springs, Colorado 80904, United States
  • GSK Investigational Site
    Stamford, Connecticut 06902, United States
  • GSK Investigational Site
    Miami, Florida 331144, United States
  • GSK Investigational Site
    Pembroke Pines, Florida 33024, United States
  • GSK Investigational Site
    West Palm Beach, Florida 33407, United States
  • GSK Investigational Site
    Atlanta, Georgia 30033, United States
  • GSK Investigational Site
    Atlanta, Georgia 30308, United States
  • GSK Investigational Site
    Atlanta, Georgia 30342, United States
  • GSK Investigational Site
    Chicago, Illinois 60614, United States
  • GSK Investigational Site
    Evansville, Indiana 47712, United States
  • GSK Investigational Site
    Wichita, Kansas 67207, United States
  • GSK Investigational Site
    New Orleans, Louisiana 70121, United States
  • GSK Investigational Site
    North Dartmouth, Massachusetts 02747, United States
  • GSK Investigational Site
    Ann Arbor, Michigan 48104, United States
  • GSK Investigational Site
    Kalamazoo, Michigan 49009, United States
  • GSK Investigational Site
    St. Louis Park, Minnesota 55426, United States
  • GSK Investigational Site
    Springfield, Missouri 65804, United States
  • GSK Investigational Site
    St. Louis, Missouri 63141, United States
  • GSK Investigational Site
    Las Vegas, Nevada 89146, United States
  • GSK Investigational Site
    Albuquerque, New Mexico 87108, United States
  • GSK Investigational Site
    Albany, New York 12206, United States
  • GSK Investigational Site
    Bronx, New York 10461, United States
  • GSK Investigational Site
    New York, New York 10022, United States
  • GSK Investigational Site
    Rochester, New York 14642, United States
  • GSK Investigational Site
    Valley Stream, New York 11580, United States
  • GSK Investigational Site
    Chapel Hill, North Carolina 27599, United States
  • GSK Investigational Site
    Greensboro, North Carolina 27401, United States
  • GSK Investigational Site
    Raleigh, North Carolina 27609, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45245, United States
  • GSK Investigational Site
    Cleveland, Ohio 44195, United States
  • GSK Investigational Site
    Independence, Ohio 44131, United States
  • GSK Investigational Site
    West Chester, Ohio 45069, United States
  • GSK Investigational Site
    Westerville, Ohio 43081, United States
  • GSK Investigational Site
    Medford, Oregon 97504-8456, United States
  • GSK Investigational Site
    Carnegie, Pennsylvania 15106, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19107-2568, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15213, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15236, United States
  • GSK Investigational Site
    Anderson, South Carolina 29621, United States
  • GSK Investigational Site
    Simpsonville, South Carolina 29681, United States
  • GSK Investigational Site
    Nashville, Tennessee 37203, United States
  • GSK Investigational Site
    Austin, Texas 78705, United States
  • GSK Investigational Site
    Austin, Texas 78745, United States
  • GSK Investigational Site
    Bellaire, Texas 77401, United States
  • GSK Investigational Site
    Houston, Texas 77030, United States
  • GSK Investigational Site
    Katy, Texas 77450, United States
  • GSK Investigational Site
    Richardson, Texas 75080, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    Salt Lake City, Utah 84107, United States
  • GSK Investigational Site
    Salt Lake City, Utah 84109, United States
  • GSK Investigational Site
    Salt Lake City, Utah 84121, United States
  • GSK Investigational Site
    West Jordan, Utah 84084, United States
  • GSK Investigational Site
    Alexandria, Virginia 22311, United States
  • GSK Investigational Site
    Seattle, Washington 98104, United States
  • GSK Investigational Site
    Seattle, Washington 98195, United States
  • GSK Investigational Site
    Wenatchee, Washington 98801, United States
  • GSK Investigational Site
    Milwaukee, Wisconsin 53209-0996, United States
09

References and documents

Publications

  • Silberstein S, Lipton RB, Goldstein J, Aurora SK, White J, Ochs-Ross R, Lener SE, McDonald SA. Evaluation of a New Fixed-dose Single Tablet of Sumatriptan Formulated with RT Technology and Naproxen Sodium (SumaRT/Nap) for the Acute Treatment of Probable Migraine without Aura. Headache 2008: presented at the American Headache Society Meeting, Boston, MA.

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2006, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2009, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2006
First posted
Oct 13, 2006
Start
Sep 2006
Primary completionActual
Feb 2008
CompletionActual
Feb 2008
Results first posted
Jul 10, 2009
Last update
Dec 16, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00387881
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 13, 2006
Start date
Sep 2006
Primary completion
Feb 2008
Completion
Feb 2008
Results posted
Jul 10, 2009
Last update
Dec 16, 2016

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sumatriptan · Naproxen

Start the discussion